Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




cfDNA Testing Accurately Detects Fetal Trisomies in Twin Pregnancies

By LabMedica International staff writers
Posted on 24 Jun 2019
Results presented in a recently published paper indicated that the performance of cfDNA (cell-free DNA) testing for trisomy 21 (Down syndrome) in twin pregnancy was similar to that reported in singleton pregnancy and was superior to that of the first‐trimester combined test or second‐trimester biochemical testing.

CfDNA testing, which involves analyzing fetal DNA in a maternal blood sample, is a non-invasiveness and highly accurate test for Down syndrome in singleton pregnancies, but its effectiveness in twin pregnancies has been unclear.

To clarify this situation, investigators at King's College Hospital (London, United Kingdom) determined a cfDNA result for 997 twin pregnancies with known birth outcome.

Targeted cfDNA testing for fetal trisomy was performed using the "Harmony" prenatal test. Harmony used Digital ANalysis of Selected Regions (DANSR) assays, which targeted sequences on chromosomes 13, 18 and 21 for chromosome quantitation and single‐nucleotide polymorphisms on chromosomes 1–12 for fetal‐fraction measurement. Products of the DANSR assays were quantified using either next‐generation sequencing or a custom microarray; both were used during the course of this study.

Results showed that the cfDNA test correctly classified 16 (94.1%) of the 17 cases of trisomy 21, nine (90.0%) of the 10 cases of trisomy 18, one (50.0%) of the two cases of trisomy 13 and 962 (99.4%) of the 968 cases without any of the three trisomies.

In addition to the fresh cfDNA test results, the investigators conducted a literature search that identified seven relevant studies, excluding their own previous papers because their data were included in the current study. Combining the populations of this study and the seven studies identified by the literature search, analysis revealed 56 trisomy‐21 and 3718 non‐trisomy‐21 twin pregnancies. The pooled weighted detection rate (DR) and false‐positive rate (FPR) were 98.2% and 0.05%, respectively.

The authors concluded that while cfDNA testing is not now recommended for use in twin pregnancies, these latest findings provide compelling evidence that mothers carrying twins should not be denied this safe and effective test.

The study was published in the June 4, 2019, online edition of the journal Ultrasound in Obstetrics & Gynecology.

Related Links:
King's College Hospital


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.